ATE412671T1 - Modifizierter faktor viii - Google Patents

Modifizierter faktor viii

Info

Publication number
ATE412671T1
ATE412671T1 AT03746308T AT03746308T ATE412671T1 AT E412671 T1 ATE412671 T1 AT E412671T1 AT 03746308 T AT03746308 T AT 03746308T AT 03746308 T AT03746308 T AT 03746308T AT E412671 T1 ATE412671 T1 AT E412671T1
Authority
AT
Austria
Prior art keywords
factor viii
fviii
modified
modified factor
immunogenic
Prior art date
Application number
AT03746308T
Other languages
English (en)
Inventor
Tim Jones
Matthew Baker
Francis Carr
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Application granted granted Critical
Publication of ATE412671T1 publication Critical patent/ATE412671T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT03746308T 2002-04-18 2003-04-17 Modifizierter faktor viii ATE412671T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02008712 2002-04-18
EP03006554 2003-03-24

Publications (1)

Publication Number Publication Date
ATE412671T1 true ATE412671T1 (de) 2008-11-15

Family

ID=29252205

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03746308T ATE412671T1 (de) 2002-04-18 2003-04-17 Modifizierter faktor viii

Country Status (15)

Country Link
US (1) US20050256304A1 (de)
EP (1) EP1495052B9 (de)
JP (1) JP2005538694A (de)
KR (1) KR20040103970A (de)
CN (1) CN1646564A (de)
AT (1) ATE412671T1 (de)
AU (1) AU2003232482A1 (de)
BR (1) BR0308860A (de)
CA (1) CA2482926A1 (de)
DE (1) DE60324406D1 (de)
ES (1) ES2319758T3 (de)
MX (1) MXPA04010061A (de)
PL (1) PL371278A1 (de)
RU (1) RU2004133761A (de)
WO (1) WO2003087161A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7485291B2 (en) 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
CA2526120A1 (en) 2003-06-03 2005-02-24 Cell Genesys, Inc. Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
KR101468345B1 (ko) 2004-11-12 2014-12-03 바이엘 헬스케어 엘엘씨 Ｆｖｉｉｉ의 부위 지향 변형
WO2006063031A2 (en) 2004-12-06 2006-06-15 Haplomics Allelic variants of human factor viii
FR2913020B1 (fr) * 2007-02-23 2012-11-23 Biomethodes Nouveaux facteurs viii pour le traitement des hemophiles de type a
WO2009014835A2 (en) * 2007-06-21 2009-01-29 Angelica Therapeutics, Inc. Modified toxins
GB0723712D0 (en) * 2007-12-04 2008-01-16 Apitope Technology Bristol Ltd Peptides
GB0801513D0 (en) * 2008-01-28 2008-03-05 Circassia Ltd Peptides from factor VIII
EP2268297A4 (de) * 2008-02-29 2011-11-16 Angelica Therapeutics Inc Modifizierte toxine
GB0908515D0 (en) * 2009-05-18 2009-06-24 Apitope Technology Bristol Ltd Peptide
CA2780763A1 (en) * 2009-11-13 2011-05-19 Puget Sound Blood Center Factor viii b cell epitope variants having reduced immunogenicity
BR112012017483A2 (pt) * 2010-01-14 2019-09-24 Haplomics Inc previsão e redução de aloimunogenicidade de terapêuticos de proteína
US8969524B2 (en) * 2010-10-27 2015-03-03 Baxter International Inc. FVIII peptides for immune tolerance induction and immunodiagnostics
EP2666782A1 (de) * 2012-05-22 2013-11-27 Imnate Sarl Gerinnungsfaktor VII mit reduzierter Immunogenität
US10272163B2 (en) 2012-12-07 2019-04-30 The Regents Of The University Of California Factor VIII mutation repair and tolerance induction
US20160038575A1 (en) * 2013-03-15 2016-02-11 Haplomics, Inc. Compositions and methods for immune tolerance induction to factor viii replacement therapies in subjects with hemophilia a
HK1220376A1 (zh) 2013-03-15 2017-05-05 Angelica Therapeutics, Inc. 修饰的毒素
JP6523244B2 (ja) * 2013-03-15 2019-05-29 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 変異体第ｖｉｉｉ因子ポリペプチドならびにそれらの製造方法および使用方法
US11441122B2 (en) 2017-10-05 2022-09-13 Epivax Inc. Regulatory T cell epitopes
CA3097943A1 (en) * 2018-04-12 2019-10-17 Biotest Ag De-immunized factor viii molecule and pharmaceutical compositions comprising the same
KR20210034013A (ko) * 2018-07-16 2021-03-29 박스알타 인코퍼레이티드 발현이 증가된 재조합 fviii 변이체들을 인코딩하는 바이러스 벡터를 이용한 혈우병의 유전적 치료법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180371B1 (en) * 1996-06-26 2001-01-30 Emory University Modified factor VIII
US20020068303A1 (en) * 1994-07-14 2002-06-06 Ruth Laub Antigenic polypeptide sequences of factor VIII, and fragments and/or epitopes of these sequences
BE1008491A3 (fr) * 1994-07-14 1996-05-07 Croix Rouge De Belgique Depart Sequence polypeptidique antigenique du facteur viii, fragments et/ou epitopes de celle-ci.
WO1997003195A1 (en) * 1995-07-11 1997-01-30 Chiron Corporation Novel factor viii:c polypeptide analogs with altered protease sites
WO1998052976A1 (en) * 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
GB9712892D0 (en) * 1997-06-20 1997-08-20 Eclagen Ltd Identification of mhc binding peptides
US6835550B1 (en) * 1998-04-15 2004-12-28 Genencor International, Inc. Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins
US6759216B1 (en) * 1998-11-06 2004-07-06 Emory University Glycosylated, low antigenicity low immunogenicity factor VIII
EP1051432B1 (de) * 1998-12-08 2007-01-24 Biovation Limited Verfahren zur verminderung der immunogenität von proteinen
WO2002096454A1 (en) * 2001-05-31 2002-12-05 D. Collen Research Foundation Vzw Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools

Also Published As

Publication number Publication date
EP1495052A1 (de) 2005-01-12
WO2003087161A1 (en) 2003-10-23
JP2005538694A (ja) 2005-12-22
KR20040103970A (ko) 2004-12-09
EP1495052B1 (de) 2008-10-29
US20050256304A1 (en) 2005-11-17
AU2003232482A1 (en) 2003-10-27
RU2004133761A (ru) 2005-07-10
DE60324406D1 (de) 2008-12-11
CN1646564A (zh) 2005-07-27
PL371278A1 (en) 2005-06-13
EP1495052B9 (de) 2009-12-16
ES2319758T3 (es) 2009-05-12
BR0308860A (pt) 2005-01-04
CA2482926A1 (en) 2003-10-23
MXPA04010061A (es) 2004-12-13

Similar Documents

Publication Publication Date Title
DE60324406D1 (de) Modifizierter faktor viii
MXPA04001982A (es) Factor ix modificado.
AU2002302255A1 (en) Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
MXPA02005576A (es) Vacuna para la prevencion y tratamiento de la enfermedad de alzheimer y otras enfermedades relacionadas con amiloides.
AU2003242305A1 (en) Hla-a24-restricted cancer antigen peptide
CY1117387T1 (el) ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ Ν-11 ΔΙΑΣΠΑΣΜΕΝΟΥ β-ΑΜΥΛΟΕΙΔΟΥΣ, ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ
MXPA04004417A (es) Anticuerpo anti-tnf alfa modificado.
UA103751C2 (ru) Иммуногенный пептид для иммунотерапии
DK2087904T3 (da) Terapeutisk anvendelse af peptider stammende fra Bcl-XL-protein i cancerpatienter
WO2008118017A3 (en) Prame derived peptides and immunogenic compositions comprising these
MXPA03008715A (es) Reduccion de la inmunogenicidad de proteinas de fusion.
DK1329458T3 (da) Peptider som sænker blodglucoseniveauer
EA201070681A1 (ru) Пептиды fviii и их применение для индукции толерантности у больных гемофилией
DE60322225D1 (en) T-zellen-epitope in erythropoietin
HUP0400703A2 (hu) Csökkentett immunogenitású módosított eritropoietin (EPO)
ATE177843T1 (de) Peptomere mit erhöhter immunogenizität
MXPA04001976A (es) Hormona de crecimiento humano modificada.
EP1499349A4 (de) Rekombinante hybrid-allergenkonstrukte mit verringerter allergenität unter beibehaltung der immunogenität des natürlichen allergens
BR0311308A (pt) Briodina 1 modificada com imunogenicidade reduzida
MXPA04004970A (es) Epitopos de linfocitos t en carboxipeptidasa g2.
ATE435660T1 (de) Immunogenes polypeptid bestehend aus optimierten kryptischen peptiden aus tumorantigenen und seine verwendungen
WO2003025014A3 (fr) Utilisation de peptides comportant des modifications de type post-traductionnel dans le cadre du traitement de pathologies auto-immunes
BR112013009276A2 (pt) peptídeos de c18orf54 e vacinas incluindo os mesmos
WO2003040176A3 (fr) Leurres peptidiques pour la preparation de medicaments destines a la prevention ou au traitement des pathologies auto-immunes, ou des troubles lies a l'apparition d'anticorps diriges contre des proteines exogenes

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties